Beta Bionics, Inc. (BBNX)

Beta Bionics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-73.2	-54.76	-44.1	-64.75	-44.1
Depreciation & Amortization	1.57	1.15	1.23	1.35	1.23
Stock-Based Compensation	16.38	6.38	5.66	6.1	5.66
Other Adjustments	13.31	11.1	10.08	-0.11	10.08
Change in Receivables	-5.16	-7.62	-4.49	-	-4.49
Changes in Inventories	-9.88	-11.44	-1.19	-	-1.19
Changes in Accounts Payable	2.1	1.52	0.72	-0.08	0.72
Changes in Accrued Expenses	7.42	6.84	1.83	-2.01	1.83
Changes in Unearned Revenue	2.06	2.46	0.34	-0.18	0.34
Changes in Other Operating Activities	-5.53	-3.9	-2.51	-0.53	-2.51
Operating Cash Flow	-50.93	-48.27	-32.45	-60.21	-32.45
Capital Expenditures	-5.3	-3.4	-0.4	-0.77	-0.4
Sale of Property, Plant & Equipment	0.05	-	0	0	0
Purchases of Investments	-327.51	-72.13	-69.3	-	-69.3
Proceeds from Sale of Investments	170	72	-	-	-
Investing Cash Flow	-162.81	-3.48	-69.69	-0.77	-69.69
Issuance of Common Stock	214.87	0.1	0.03	0.39	0.03
Net Common Stock Issued (Repurchased)	214.87	0.1	0.03	0.39	0.03
Issuance of Preferred Stock	-	59.66	101	56.39	101
Net Preferred Stock Issued (Repurchased)	-	59.66	101	56.39	101
Other Financing Activities	-	-4.15	-	-	-
Financing Cash Flow	214.87	55.62	101.03	56.78	101.03
Net Cash Flow	1.14	3.87	-1.11	-4.2	-1.11
Free Cash Flow	-56.22	-51.67	-32.85	-60.98	-32.85
FCF Margin	-56.08%	-79.34%	-273.84%	-34067.04%	-
Free Cash Flow Per Share	-1.39	-8.12	-6.19	-12.20	-
Levered Free Cash Flow	-80.75	-61.53	-44.09	-66.97	0.01
Unlevered Free Cash Flow	-79.24	-52.03	-35.84	-68.06	0.01

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q